I found no systematic review. I found nine RCTs comparing griseofulvin with other oral antifungals in tinea capitis (Table 34.1).
I found four RCTs. In two RCTs1819 where T. tonsurans was the most commonly isolated organism, griseofulvin at doses of 10-20 mg/kg/day18 and 250-500 mg/day19 were compared with ketoconazole 3-3-6-6 mg/ kg/day18 and 200 mg/day,19 for 12 and 6 weeks, respectively. There were no statistically significant differences between the mycological cure rate of the two drugs. Cure rates in the griseofulvin groups at the end of treatment were 96%18 and 57-1%.19 A small RCT20 of 47 children compared griseofulvin 350 mg/day for 6 weeks with ketoconazole 100 mg/day for 6 weeks in inflammatory tinea capitis (T. mentagrophytes and M. canis). At the end of treatment, 80% and 100% of children respectively had improved clinically, but no mycological data were reported. An RCT of unknown blinding21 done in 63 children where Trichophyton spp. predominated, compared griseofulvin 15 mg/kg/day with ketoconazole 5 mg/kg/day, each given as a single daily dose, and treatment stopped when there was complete cure or after 6 months. After 8 weeks' therapy 92% of the patients given griseofulvin had complete cure of their infection compared with only 59% of ketoconazole-treated patients. After 12 weeks 96% of griseofulvin patients were mycologically cured compared with 74% of the ketoconazole-treated group. Hair sample cultures took significantly longer to become sterile in ketoconazole-treated (median 8 weeks) than in griseofulvin-treated (4 weeks) patients.
I found one RCT22 done in 34 children where the majority of fungal organisms were M. canis, comparing 6 weeks of ultramicrosized griseofulvin 500 mg/day and itraconazole 100 mg/day and a follow up of 14 weeks that showed a complete cure rate of 88% for the two drugs.
I found four RCTs. A double-blind RCT23 compared 140 children from Pakistan, of whom 87 had T. violaceum tinea capitis. They were treated with either terbinafine (by weight) for 4 weeks or with griseofulvin 6-12 mg/kg/day for 8 weeks. After 12 weeks, 93% of the terbinafine group were completely cured compared with 80% of the griseofulvin group; not a significant difference. A double-blind RCT24 evaluated 50 children from Peru, 74% of whom had T. tonsurans infections. Half were treated with terbinafine according to weight, for 4 weeks plus 4 weeks with placebo; the other half received microsized griseofulvin according to weight for 8 weeks. After 8 weeks of treatment, complete cure was noted in 76% of the griseofulvin group and in 72% of terbinafine group, but 4 weeks later the complete cure rate increased to 76% in the terbinafine group but in the griseofulvin group it had fallen to 44%, a statistically significant difference. In a large RCT,25 T. tonsurans accounted for 77% of the terbinafine group and 88% of the griseofulvin group; Microsporum spp. accounted for 14% of both groups. The RCT compared 8 weeks of griseofulvin suspension 10 mg/kg/day with 4 weeks of terbinafine. Complete cure rates at week 24 were 64% with terbinafine and 67% with griseofulvin - no significant difference. However, there was a trend to better responses in Microsporum spp. infections with 8 weeks of griseofulvin than with 4 weeks of terbinafine. In another RCT26 the complete cure rate at the final follow up visit (week 12) was 74% in the group treated with 8 weeks' ultramicrosized griseofulvin, compared with 78% of the group treated with 4 weeks' terbinafine, with no significant differences between M. canis and Trichophyton spp. infections.
Was this article helpful?
Do You Suffer From the Itching and Scaling of Psoriasis? Or the Chronic Agony of Psoriatic Arthritis? If so you are not ALONE! A whopping three percent of the world’s populations suffer from either condition! An incredible 56 million working hours are lost every year by psoriasis sufferers according to the National Psoriasis Foundation.